Brought to you by 
TolerRx brings in $35.6mm with its latest venture round
21 Sep 2006
Executive Summary
TolerRx (immune system therapeutics) has raised $35.6mm with its latest venture round. New investor FrontPoint Partners led the round and was joined by other new backers Mesirow Financial, Swiss Re, QVT Fund, IBT Management, Brookstone Capital, and the Juvenile Diabetes Research Foundation. Returning participants included Skyline Ventures, Bear Stearns, Sprout Group, Rho Ventures, Artal Services, and HealthCare Ventures. TolerRx will use the funds to continue developing the anti-CD3 monoclonal antibody TRX4, its lead candidate that is in Phase II for Type I diabetes and Phase I for psoriasis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TolerRx brings in $35.6mm with its latest venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice